BioWorld Asia

July 19, 2006

Actelion, Roche Sign $630M Autoimmunity Product Deal

Shrugging off recent disappointments in the clinic, Actelion AG signed what is likely to be one of the landmark licensing deals in European biotechnology in 2006. (BioWorld International) Read More

DeCode Stock Sale To Raise $30M For Multidrug Pipeline

Motility Control Proteins Might Play Part In Pancreatic Cancer

Crucell Shares Fall After Aerugen Program Ended

ProStrakan Secures Deal, Raises £11M In Placement

Nasdaq In Lead, But Potential LSE Merger Raises Questions

Cellectis, Lexicon Genetics Exchange Rights To Patents

Devices In Past, Medisys Now Complete As Investing Firm

Advanced Therapies Under Scrutiny At EU Parliament

Astion Brings In DKK50M For Dermatology Pipeline

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 30, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026